Filing Details

Accession Number:
0001415889-21-002642
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-05-21 18:45:16
Reporting Period:
2021-05-19
Accepted Time:
2021-05-21 18:45:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1285819 Omeros Corp OMER Pharmaceutical Preparations (2834) 911663741
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1472160 Md A Gregory Demopulos C/O Omeros Corporation
201 Elliott Avenue West
Seattle WA 98119
Chairman, Ceo & President No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-05-19 36,857 $4.10 2,063,843 No 4 M Direct
Common Stock Disposition 2021-05-19 36,857 $17.07 2,026,986 No 4 S Direct
Common Stock Acquisiton 2021-05-20 36,856 $4.10 2,063,842 No 4 M Direct
Common Stock Disposition 2021-05-20 36,856 $14.96 2,026,986 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2021-05-19 36,857 $0.00 36,857 $4.10
Common Stock Stock Option (right to buy) Disposition 2021-05-20 36,856 $0.00 36,856 $4.10
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
110,569 2022-01-07 No 4 M Direct
73,713 2022-01-07 No 4 M Direct
Footnotes
  1. Open market sale pursuant to a previously established Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2020 for expiring options. The trading schedule, including sale dates and the number of shares to be sold, was established at the time of the trading plan's adoption in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
  2. This transaction was executed in multiple trades at prices ranging from $16.92 to $17.60; the price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
  3. This transaction was executed in multiple trades at prices ranging from $13.87 to $15.27; the price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
  4. The shares subject to this option vested and became exercisable over 48 monthly installments, with a vesting commencement date of April 1, 2011.